Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease

Therapeutic Drug Monitoring

Volumn 29, Issue 5, 2007, Pages 619-625

  Brooks, Alenka J ^a   Begg, Evan J ^a,b   Zhang, Mei ^a,b   Frampton, Chris M ^a,b   Barclay, Murray L ^a,b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Inflammatory bowel disease; Methotrexate; Methotrexate polyglutamates; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

FOLIC ACID; MESALAZINE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; CROHN DISEASE; DECREASED APPETITE; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MONITORING; ENTERITIS; ERYTHROCYTE; FEMALE; FORGETFULNESS; HAIR LOSS; HUMAN; LIVER FUNCTION TEST; MALE; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STEADY STATE; TREATMENT DURATION; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; DRUG MONITORING; ERYTHROCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID;

EID: 34848925807     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31811f39bb     Document Type: Article

References (43)

1. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989;110:353-356.
2. Ardizzone SB, Manzionna G, Imbesi V, et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis. 2003;35:619-627.
3. Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology. 1999;46:1724-1729.
4. Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol. 1997;92:2203-2209.
5. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med. 1995;332:292-297.
6. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000;342:1627-1632.
7. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-1233.
8. Derjiks LJJ, Gilissen PM, Hooymans PM, et al. Review article: thiopurines in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2006;24:715-729.
9. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohns disease: a meta-analysis. Ann Intern Med. 1995;123:132-142.
10. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiology and Drug Safety. 2004;13:563-567.
11. Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:407-420.
12. Chladek J, Martinkova J, Simkova M, et al. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment. Eur J Clin Pharmacol. 1998;53:437-444.
13. Kozarek RA, Patterson DJ, Gelfand MD, et al. Long term use of methotrexate in inflammatory bowel disease. Gastroenterology. 1992;102:A648.
14. Schroder O, Blumenstein I, Schulte-Bockholt A, et al. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Alimentary Pharmacology & Therapeutics. 2004;19:295-301.
15. Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2002;16:693-697.
16. Grove ML, Hassell AB, Hay EM, et al. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM. 2001;94:309-319.
17. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1995;22:844-849.
18. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics. 1999;13:1597-1604.
19. Grim J, Chladek J, Martinkova J. Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases. Clin Pharmacokinet. 2003;42:139-151.
20. Hoffbrand AV, Weir DG. The history of folic acid. Br J Haematol. 2001;113:579-589.
21. Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemotherapy & Pharmacology. 1988;21:145-149.
22. Dervieux T, Furst D, Lein DO, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766-2774.
23. Schmiegelow K, Schroder H, Pulczynska MK, et al. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: relation of bone-marrow and hepatotoxicity to the concentration of methotrexate in erythrocytes. Cancer Chemotherapy & Pharmacology. 1989;25:65-69.
24. Angelis-Stoforidis P, Vajda FJE, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol. 1999;17:313-320.
25. Schroder H, Clausen N, Ostergaard E, et al. Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment. Cancer Chemotherapy & Pharmacology. 1986;16:190-193.
26. Schmiegelow K, Schroder H, Gustafsson G, et al. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol. 1995;13:345-351.
27. Gearry RB, Richardson A, Frampton CMA, et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiological study. Inflammatory Bowel Diseases. 2006;12:936-943.
28. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
29. Sostegni R, Daperno M, Scaglione N, et al. Review article: Crohn's disease: monitoring disease activity. Alimentary Pharmacology & Therapeutics. 2003;17(Suppl):11-17.
30. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
31. Higgins PD, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782-788.
32. Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479-1484.
33. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
34. Dervieux T, Lein DO, Marcelletti J, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem. 2003;49:1632-1641.
35. Bland JM, Altman DG. Statistics notes: measurement error. BMJ. 1996;313:744.
36. Allegra CJ, Drake JC, Jolivet J, et al. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985;82:4881-4885.
37. Baggott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazole-4- carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986;236:193-200.
38. Guidance for Industry, Bioanalytical Method Validation. US Food and Drug Administration; 2001.
39. Dervieux T, Furst D, Lein DO, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentered cross sectional observational study. Ann Rheum Dis. 2005;64:1180-1185.
40. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163-172.
41. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993;92:2675-2682.
42. Ahern MJ, Kevat S, Hill W, et al. Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings. Ann Rheum Dis. 1991;50:477-480.
43. Kamen BA, Nylen PA, Camitta BM, et al. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol. 1981;49:355-360.